Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 231 publications
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.
Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026
Pre-infusion plasma proteomics identifies an endothelial-immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma.
Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026
The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.
Journal: Blood
Published: April 10, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England)
Published: March 18, 2026
A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.
Journal: bioRxiv : the preprint server for biology
Published: February 06, 2026
Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.
Journal: Blood cancer journal
Published: January 27, 2026
A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.
Journal: EJHaem
Published: January 26, 2026
A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.
Journal: Blood cancer discovery
Published: January 20, 2026
Safety of concurrent radiation therapy with the antibody-drug conjugate polatuzumab vedotin in relapsed or refractory aggressive B-cell lymphomas.
Journal: Practical radiation oncology
Published: January 07, 2026
Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.
Journal: International journal of clinical oncology
Published: January 06, 2026
Last Updated: 09/26/2026